OverviewSuggest Edit

Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. Its therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells.

TypePublic
Founded2017
HQPhiladelphia, PA, US
Websitecabalettabio.com

Latest Updates

Employees (est.) (Sept 2019)19
Share Price (Sept 2021)$12.4(+8%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cabaletta Bio

Steven Nichtberger

Steven Nichtberger

President, Chief Executive Officer, and Co-Founder, Chairman
Gwendolyn Binder

Gwendolyn Binder

Executive Vice President, Science & Technology
Catherine Bollard

Catherine Bollard

Director
David J. Chang

David J. Chang

Chief Medical Officer
Richard Henriques

Richard Henriques

Director
Arun Das

Arun Das

Executive Director of New Product Planning and Business Development
Show more

Cabaletta Bio Office Locations

Cabaletta Bio has an office in Philadelphia
Philadelphia, PA, US (HQ)
Cira Centre, 2929 Arch St #600
Show all (1)

Cabaletta Bio Financials and Metrics

Cabaletta Bio Revenue

USD

Net income (Q1, 2021)

(9.7m)

EBIT (Q1, 2021)

(9.7m)

Market capitalization (17-Sept-2021)

308.6m

Closing stock price (17-Sept-2021)

12.4

Cash (31-Mar-2021)

97.3m
Cabaletta Bio's current market capitalization is $308.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

250.0k1.7m7.0m12.5m

R&D expense

4.5m11.7m21.4m

Operating expense total

250.0k6.2m18.7m33.8m

EBIT

(250.0k)(6.2m)(18.7m)(33.8m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

1.8m3.3m2.9m3.2m

R&D expense

3.2m4.6m5.3m6.6m

Operating expense total

5.0m7.9m8.2m9.7m

EBIT

(5.0m)(7.9m)(8.2m)(9.7m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.0k33.0m136.2m101.4m

Prepaid Expenses

4.3m4.9m

Current Assets

140.6m113.5m

PP&E

815.0k890.0k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

75.3m71.0m131.0m112.1m97.3m

Prepaid Expenses

708.0k3.1m3.7m3.7m

Current Assets

71.7m134.1m123.5m105.8m

PP&E

540.0k739.0k806.0k1.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(250.0k)(12.2m)(16.9m)(33.3m)

Depreciation and Amortization

104.0k354.0k

Accounts Payable

189.0k234.0k246.0k555.0k

Cash From Operating Activities

(4.7m)(16.0m)(26.8m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(1.0m)(6.9m)(11.5m)(7.5m)(15.6m)(9.7m)

Depreciation and Amortization

53.0k76.0k154.0k116.0k

Accounts Payable

3.0k(120.0k)552.0k1.2m198.0k(329.0k)

Cash From Operating Activities

(1.7m)(6.1m)(8.2m)(4.9m)(12.6m)(8.7m)
Show all financial metrics

Cabaletta Bio Operating Metrics

Oct, 2019

Discovery Stage Products

2

Drugs in Development

4

Phase I Trials Products

1

Pre-Clinical Phase Products

1
Show all operating metrics

Cabaletta Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Cabaletta Bio Online and Social Media Presence

Embed Graph

Cabaletta Bio News and Updates

Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been ap…

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participa…

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort –

Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

       – Company continues to make progress on the DesCAARTes™ trial for DSG3-CAART; expects to report second and third cohort safety data in 3Q21 and 4Q21, respectively, and data on target engagement 3 to 6 months after each completed cohort –

Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

Dr. Brun’s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta’s rapidly emerging pipeline

Cabaletta Bio to Present at the Jefferies Healthcare Conference

PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., Pr…
Show more

Cabaletta Bio Frequently Asked Questions

  • When was Cabaletta Bio founded?

    Cabaletta Bio was founded in 2017.

  • Who are Cabaletta Bio key executives?

    Cabaletta Bio's key executives are Steven Nichtberger, Gwendolyn Binder and Catherine Bollard.

  • How many employees does Cabaletta Bio have?

    Cabaletta Bio has 19 employees.

  • Who are Cabaletta Bio competitors?

    Competitors of Cabaletta Bio include Lupagen, Cristcot and LQT Therapeutics.

  • Where is Cabaletta Bio headquarters?

    Cabaletta Bio headquarters is located at Cira Centre, 2929 Arch St #600, Philadelphia.

  • Where are Cabaletta Bio offices?

    Cabaletta Bio has an office in Philadelphia.

  • How many offices does Cabaletta Bio have?

    Cabaletta Bio has 1 office.